{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.2020T",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "T",
            "position": "2020"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "D",
            "position": "2020"
          },
          "Description in input context": "c.2020T (p.G213D)"
        },
        {
          "HGVS": "NM_001126112.3:c.2019S",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "T",
            "position": "2019"
          },
          "Description in input context": "c.2019S (p.G2019T)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's Disease",
    "MONDO": "MONDO:0005679"
  },
  "Experiment Method": [
    {
      "Assay Method": "Binding Assays, Enzymatic Assays",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "Human dopant serum",
        "Description": "Cells were incubated with LRRK2 variants in the presence of ATP"
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.2020T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Reduced ATP binding affinity (wild-type: 2-fold lower ATP K_d)",
          "Result Description": "At 1 mM ATP, wild-type LRRK2 had higher ATP binding affinity compared to I2020T variant."
        },
        {
          "Variant": "NM_001126112.3:c.2019S",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Reduced ATP binding affinity (wild-type: 6-fold higher ATP K_d)",
          "Result Description": "At 1 mM ATP, wild-type LRRK2 had lower ATP binding activity compared to G2019S variant."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed with each variant"
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was tested in triplicate for consistent results"
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 cDNA was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Beta-actin cDNA was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Not mentioned in the literature.",
        "Counts": "N/A"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Not mentioned in the literature.",
        "Counts": "N/A"
      },
      "Statistical analysis method": "Paired two-sample t-test was used to compare ATP binding activity between wild-type and mutant LRRK2 variants.",
      "Threshold for normal readout": {
        "Threshold for normal readout": "ATP binding activity ≥90% of wild-type level at 1 mM.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "ATP binding activity ≤80% of wild-type level at 1 mM.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes, this experimental protocol is generally applicable to the study of Parkinson's Disease."
      }
    }
  ]
}